Sai Parenteral’s IPO
Market Sentiment
IPO Details
IPO Reservation
Market Lot Size
Financial Analysis
| Metric | 2023 | 2024 | 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 97.03 | 155.18 | 163.74 | 89.43 |
| Expense | 89.78 | 142.63 | 143.84 | 78.27 |
| Profit (PAT) | 4.38 | 8.42 | 14.43 | 7.76 |
| Total Assets | 133.96 | 268.10 | 272.39 | 376.24 |
| Company | EPS | P/E | Market Cap (Cr) |
|---|---|---|---|
| Sai Life Sciences Limited | 8.83 | 107.70 | 8 |
| InnovaCaptab Limited | 22.41 | 32.45 | 13 |
| Senores Pharmaceuticals Limited | 16.12 | 64.30 | 7 |
| Gland Pharma Limited | 42.40 | 44.71 | 8 |
| Industry Average | - | 62.29 | - |
Promoters: Anil Kumar Karusala, Vijitha Gorrepati and Karusala Aruna
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 3,69,08,823 | 61.23% |
Strengths & Risks
- Solid profit margin — 8.8%.
- Strong return on equity — 15%.
- Mostly fresh capital — proceeds fund the company's growth, not an exit.
No major red flags in the available data.
Auto-generated from live GMP, subscription, valuation and financial data. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Sai Parenteral’s Ltd., founded in 2001, is one of the leading pharmaceutical companies focused on R&D and manufacturing of pharmaceutical products. The firm operates in 2 main business areas: makes and sells its own branded medicines, and also manufactures medicines for other companies internationally. Its product offerings include a wide range of medicines for various health conditions, like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals, and supplements (VMS), analgesics, and dermatology. Its medicines are available in various forms like tablets, injections, and syrups. Sai Parenteral’s major clients are government agencies, pharmaceutical companies, public and private hospitals, and large distributors in India. The firm operates 5 manufacturing facilities in India, mainly located in Hyderabad, known for developing medicines with international quality certifications.
| Purpose | Amount (Cr) |
|---|---|
| Capacity expansion and upgradation of manufacturing facilities | 110.80 |
| Establishment of a new R&D Centre; | 18.02 |
| Repayment / prepayment of certain outstanding borrowings | 20.00 |
| Working capital requirements | 33.00 |
| Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and | 36.00 |
| General corporate purposes | - |
Resources & Documents
Sai Parenteral’s Ltd., Plot No 39, 5th floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, K.V.Rangareddy, Seri Lingampally, Hyderabad, Telangana, 500032
Sai Parenteral’s has set a price band of Rs 372–Rs 392 per share for an issue size of Rs 409 crore. The stock listed with a 3.32% gain versus its issue price on April 02, 2026.
Sai Parenteral’s Ltd., founded in 2001, is one of the leading pharmaceutical companies focused on R&D and manufacturing of pharmaceutical products. The firm operates in 2 main business areas: makes and sells its own branded medicines, and also manufactures medicines for other companies internationally.
The issue is promoted by Anil Kumar Karusala, Vijitha Gorrepati and Karusala Aruna with Arihant Capital Markets Ltd. acting as lead manager. Net proceeds will primarily be used towards Capacity expansion and upgradation of manufacturing facilities (Rs 111 crore) and Establishment of a new R&D Centre; (Rs 18 crore).
Final subscription data records overall subscription at 1.05x, retail at 0.12x, QIB at 1.71x, NII at 2.36x.
On fundamentals, the company is posting revenue growth of 5.5%, a profit margin of 8.8%, return on equity of 15.1% in its most recent reported period. Listed peers in this segment include InnovaCaptab Limited (P/E 32.45x, market cap Rs 13 crore) and Sai Life Sciences Limited (P/E 107.70x, market cap Rs 8 crore) — useful reference points when evaluating the issue's pricing relative to where the broader sector are trading.
Our data-driven engine currently flags this issue as an Avoid view — key indicators are weak enough that the risk-reward looks unfavourable for now. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Sai Parenteral’s IPO GMP — What It Means
No active grey market premium has been recorded for Sai Parenteral’s IPO yet. GMP is an unofficial, dealer-quoted indicator of expected listing-day demand — not a guaranteed listing price — and it can change quickly once bidding opens.
See the full Sai Parenteral’s GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
No comments yet. Be the first to share your opinion!